Integrating ARPI RWE Into mCSPC Treatment Decisions

Panelists discuss how real-world evidence (RWE) is increasingly informing treatment decisions in metastatic castration-sensitive prostate cancer (mCSPC), complementing randomized clinical trial data by capturing outcomes in broader, more diverse populations. They emphasize that confidence in applying RWE depends on study quality—well-defined cohorts, appropriate statistical balancing, and transparent reporting of potential biases. When such rigor is present, RWE offers clinicians meaningful insight into how androgen receptor pathway inhibitors (ARPIs) perform across different health care settings, age groups, and comorbidity profiles.

Panelists discuss how RWE contributes to refining treatment algorithms for agents such as apalutamide, enzalutamide, and abiraterone. While all 3 remain standard options supported by robust clinical data, RWE helps identify which patients benefit most in everyday practice—those with multiple comorbidities, those treated in community settings, or populations historically underrepresented in trials. Findings on tolerability, adherence, and duration of therapy from real-world studies allow clinicians to better match each ARPI to patient characteristics, aligning therapy with real-life health demands and preferences.

Panelists discuss how RWE ultimately strengthens shared decision-making and care personalization. By integrating evidence from both controlled trials and practical experience, clinicians can discuss not only how well a drug works in theory but how it performs for patients like those they treat daily. This approach ensures that guideline-concordant decisions also reflect patient individuality and lived experience, bridging data and compassion in prostate cancer care.